This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Celio L, Antonuzzo A, Aapro MS. Comment on dexamethasone-sparing on days 2-4 with combined Palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer. 2024;130:895–6.
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, et al. Br J Cancer. 2024;130:224–32.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, et al. Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study. Oncologist. 2021;26:e1854–61.
Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28:1260–7.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:242–9.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782–97.
NCCN Guidelines Version 1. 2024 Antiemesis [Internet]. National Comprehensive Cancer Network. 2023. [cited 17 Feb 2024]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, Chan A, et al. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer. 2023. https://doi.org/10.1007/s00520-023-08221-4.
Wang DY, Chen Y, Zhang Y, Shen YQ. The balance between the effectiveness and safety for chemotherapy-induced nausea and vomiting of different doses of olanzapine (10 mg versus 5 mg): a systematic review and meta-analysis. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.705866.
Author information
Authors and Affiliations
Contributions
HM, NI, and TEN contributed to the conception of the manuscript. HM and NI contributed to the initial draft of the manuscript. TEN contributed to critically reviewing and revising the manuscript. HM, NI, and TEN approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
NI reports grant from Taiho Pharmaceutical Co., Ltd., TEN reports grants from Sumitomo Dainippon Pharma Co., Ono Pharmaceutical Co., Taiho Pharmaceutical Co., Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Sanofi K.K., Nippon Kayaku Co., MSD K.K., and Eli Lilly Japan K.K.; and reports personal fees from Thyas Co. Ltd., Rebirthel Co., Ltd., Japan Clinical Research Operations, Sumitomo Dainippon Pharma Co., Boehringer Ingelheim, Bristol-Myers Squibb, Ono Pharmaceutical Co., Taiho Pharmaceutical Co., Amgen, Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Sanofi K.K., Novartis Japan, Nippon Kayaku Co., MSD K.K., Eli Lilly Japan K.K., Bayer Yakuhin, Pfizer Japan Inc., Daiichi, Sankyo Co., Yakult Honsha Co., Nipro Co, Merck Serono Co., AstraZeneca, IQVIA, and GlaxoSmithKline. All other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Minatogawa, H., Izawa, N. & Nakajima, T.E. Reply to L. Celio et al.. Br J Cancer (2024). https://doi.org/10.1038/s41416-024-02708-5
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41416-024-02708-5